

Refine Search

Search Results -

Terms	Documents
L3 and (514/\$ or 560/\$)	31

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L5

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, April 11, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

<u>L5</u>	13 and (514/\$ or 560/\$)	31	<u>L5</u>
<u>L4</u>	GABAPENTIN adj7 (TANNATE OR TANNIC ACID OR TAN\$9)	9	<u>L4</u>
<u>L3</u>	GABAPENTIN same (TANNATE OR TANNIC ACID OR TAN\$9)	43	<u>L3</u>
<u>L2</u>	GABAPENTIN AND (TANNATE OR TANNIC ACID OR TAN\$9)	907	<u>L2</u>

DB=USPT; PLUR=YES; OP=ADJ

<u>L1</u>	7141606.pn.	1	<u>L1</u>
-----------	-------------	---	-----------

END OF SEARCH HISTORY

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 10 of 31 returned.

☐ 1. Document ID: US 20070060652 A1

L5: Entry 1 of 31

File: PGPB

Mar 15, 2007

PGPUB-DOCUMENT-NUMBER: 20070060652

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20070060652 A1

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

PUBLICATION-DATE: March 15, 2007

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser; Matthew Oliver	Apex	NC	US
Thor; Karl Bruce	Morrisville	NC	US
Burgard; Edward C.	Chapel Hill	NC	US
Brettman; Lee R.	Sudbury	MA	US
Landau; Steven B.	Wellesley	MA	US
Ricca; Daniel J.	Rougemont	NC	US

US-CL-CURRENT: [514/561](#); [514/618](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20070020332 A1

L5: Entry 2 of 31

File: PGPB

Jan 25, 2007

PGPUB-DOCUMENT-NUMBER: 20070020332

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20070020332 A1

TITLE: Tannate compositions, methods of making and methods of use

PUBLICATION-DATE: January 25, 2007

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kiel; Jeffrey S.	Gainesville	GA	US
Thomas; H. Greg	Carrollton	GA	US

Mani; Narasimhan

Port Jefferson

NY

US

US-CL-CURRENT: 424/464; 514/225.8, 514/23, 514/255.04, 514/394

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 3. Document ID: US 20060276542 A1

L5: Entry 3 of 31

File: PGPB

Dec 7, 2006

PGPUB-DOCUMENT-NUMBER: 20060276542

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060276542 A1

TITLE: Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators

PUBLICATION-DATE: December 7, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser; Matthew Oliver	Apex	NC	US
Thor; Karl Bruce	Morrisville	NC	US
Burgard; Edward C.	Chapel Hill	NC	US
Brettman; Lee R.	Sudbury	MA	US
Landau; Steven B.	Wellesley	MA	US
Ricca; Daniel J.	Rougermont	NC	US

US-CL-CURRENT: 514/551; 514/561, 514/621, 514/626

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 4. Document ID: US 20060264509 A1

L5: Entry 4 of 31

File: PGPB

Nov 23, 2006

PGPUB-DOCUMENT-NUMBER: 20060264509

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060264509 A1

TITLE: Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators

PUBLICATION-DATE: November 23, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser; Matthew Oliver	Apex	NC	US
Thor; Karl Bruce	Morrisville	NC	US
Burgard; EdwardC	Chapel Hill	NC	US

Brettman; Lee R.	Sudbury	MA	US
Landau; Steven B.	Wellesley	MA	US
Ricca; Daniel J.	Rougemont	NC	US

US-CL-CURRENT: [514/561](#); [514/621](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 5. Document ID: US 20060247311 A1

L5: Entry 5 of 31

File: PGPB

Nov 2, 2006

PGPUB-DOCUMENT-NUMBER: 20060247311

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060247311 A1

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

PUBLICATION-DATE: November 2, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser; Matthew Oliver	Apex	NC	US
Thor; Karl Bruce	Morrisville	NC	US
Burgard; Edward C.	Chapel Hill	NC	US
Brettman; Lee R.	Sudbury	MA	US
Landau; Steven B.	Wellesley	MA	US
Ricca; Daniel J.	Rougemont	NC	US

US-CL-CURRENT: [514/551](#); [514/561](#), [514/626](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 6. Document ID: US 20060241145 A1

L5: Entry 6 of 31

File: PGPB

Oct 26, 2006

PGPUB-DOCUMENT-NUMBER: 20060241145

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060241145 A1

TITLE: Piperidine derivative crystal, process for producing the same, and use

PUBLICATION-DATE: October 26, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ikeura; Yoshinori	Osaka		JP
Hashimoto; Tadatoshi	Osaka		JP

Shirai; Junya	Osaka	JP
Takeshi; Yoshikawa	Osaka-shi	JP
Nakatani; Hiroshi	Osaka	JP
Yamano; Mitsuhsa	Osaka	JP
Mizuno; Masahiro	Osaka	JP
Irie; Hiroyuki	Osaka	JP

US-CL-CURRENT: 514/326; 546/210

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 7. Document ID: US 20060240007 A1

L5: Entry 7 of 31

File: PGPB

Oct 26, 2006

PGPUB-DOCUMENT-NUMBER: 20060240007

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060240007 A1

TITLE: Method for treating dementia or Alzheimer's disease

PUBLICATION-DATE: October 26, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sanders; Martin E.	Hillsborough	CA	US

US-CL-CURRENT: 424/144.1; 514/214.01, 514/319

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 8. Document ID: US 20060205789 A1

L5: Entry 8 of 31

File: PGPB

Sep 14, 2006

PGPUB-DOCUMENT-NUMBER: 20060205789

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060205789 A1

TITLE: Gacyclidine formulations

PUBLICATION-DATE: September 14, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Lobl; Thomas Jay	Valencia	CA	US
Schloss; John Vinton	Valencia	CA	US
McCormack; Stephen Joseph	Claremont	CA	US
Nagy; Anna Imola	Valencia	CA	US

Pananen; Jacob E.

Los Angeles

CA

US

US-CL-CURRENT: 514/326

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 9. Document ID: US 20060199805 A1

L5: Entry 9 of 31

File: PGPB

Sep 7, 2006

PGPUB-DOCUMENT-NUMBER: 20060199805

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060199805 A1

TITLE: Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders

PUBLICATION-DATE: September 7, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Pyke; Robert	New Fairfield	CT	US
Ceci; Angelo	Mittelbiberach		DE

US-CL-CURRENT: 514/220; 514/221, 514/381, 514/419, 514/521, 514/649

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 10. Document ID: US 20060167052 A1

L5: Entry 10 of 31

File: PGPB

Jul 27, 2006

PGPUB-DOCUMENT-NUMBER: 20060167052

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060167052 A1

TITLE: Piperidine derivative, process for producing the same, and use

PUBLICATION-DATE: July 27, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ikeura; Yoshinori	Osaka		JP
Hashimoto; Tadatoshi	Osaka		JP
Tarui; Naoki	Nara		JP
Shirai; Junya	Hyogo		JP
Yamashita; Masayuki	Hyogo		JP

US-CL-CURRENT: 514/326; 546/210

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D:
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L3 and (514/\$ or 560/\$)	31

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 11 through 20 of 31 returned.

☐ 11. Document ID: US 20060142337 A1

L5: Entry 11 of 31

File: PGPB

Jun 29, 2006

PGPUB-DOCUMENT-NUMBER: 20060142337

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060142337 A1

TITLE: Piperidine derivative and use thereof

PUBLICATION-DATE: June 29, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ikeura; Yoshinori	Osaka		JP
Hashimoto; Tadatoshi	Osaka		JP
Nishida; Haruyuki	Osaka		JP
Shirai; Junya	Osaka		JP
Sakauchi; Nobuki	Osaka		JP

US-CL-CURRENT: [514/317](#); [546/216](#), [546/223](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 12. Document ID: US 20060141034 A1

L5: Entry 12 of 31

File: PGPB

Jun 29, 2006

PGPUB-DOCUMENT-NUMBER: 20060141034

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060141034 A1

TITLE: GABA analog prodrug sustained release oral dosage forms

PUBLICATION-DATE: June 29, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Cundy; Kenneth C.	Redwood City	CA	US
Sastry; Srikonda	Sunnyvale	CA	US
Leung; Manshiu	Daly City	CA	US
Kadri; Balaji V.	Tampa	FL	US

Stach; Paul E.

Plymouth

MN

US

US-CL-CURRENT: 424/468; 514/548

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMCC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 13. Document ID: US 20060035889 A1

L5: Entry 13 of 31

File: PGPB

Feb 16, 2006

PGPUB-DOCUMENT-NUMBER: 20060035889

PGPUB-FILING-TYPE:

DOCUMENT-IDENTIFIER: US 20060035889 A1

TITLE: Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists

PUBLICATION-DATE: February 16, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Tedford; Clark E.	Poulsbo	WA	US
Napier; Tavye Celeste	Maywood	IL	US

US-CL-CURRENT: 514/220

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMCC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 14. Document ID: US 20050239890 A1

L5: Entry 14 of 31

File: PGPB

Oct 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050239890

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20050239890 A1

TITLE: Methods for decreasing detrusor muscle overactivity

PUBLICATION-DATE: October 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser, Matthew Oliver	Apex	NC	US
Thor, Karl Bruce	Morrisville	NC	US
Burgard, Edward C.	Chapel Hill	NC	US
Brettman, Lee R.	Sudbury	MA	US
Landau, Steven B.	Wellesley	MA	US
Ricca, Daniel J.	Rougemont	NC	US

US-CL-CURRENT: 514/561; 514/617, 514/618

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K/M/C	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	---------

☐ 15. Document ID: US 20040198822 A1

L5: Entry 15 of 31

File: PGPB

Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198822

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040198822 A1

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Fraser, Matthew Oliver	Apex	NC	US
Thor, Karl Bruce	Morrisville	NC	US
Burgard, Edward C.	Chapel Hill	NC	US
Brettman, Lee R.	Sudbury	MA	US
Landau, Steven B.	Wellesley	MA	US
Ricca, Daniel J.	Rougemont	NC	US

US-CL-CURRENT: 514/561

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	K/M/C	Draw. D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-------	---------

☐ 16. Document ID: US 20040192618 A1

L5: Entry 16 of 31

File: PGPB

Sep 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040192618

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040192618 A1

TITLE: Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use

PUBLICATION-DATE: September 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kiel, Jeffrey S.	Gainesville	GA	US
Thomas, H. Greg	Villa Rica	GA	US
Mani, Narasimhan	Port Jefferson	NY	US

US-CL-CURRENT: 514/23; 536/18.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 17. Document ID: US 20040192617 A1

L5: Entry 17 of 31

File: PGPB

Sep 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040192617

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040192617 A1

TITLE: Process for preparing phenolic acid salts of gabapentin

PUBLICATION-DATE: September 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kiel, Jeffrey S.	Gainesville	GA	US
Thomas, H. Greg	Villa Rica	GA	US
Mani, Narasimhan	Port Jefferson	NY	US

US-CL-CURRENT: 514/23; 514/561

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 18. Document ID: US 20040192616 A1

L5: Entry 18 of 31

File: PGPB

Sep 30, 2004

PGPUB-DOCUMENT-NUMBER: 20040192616

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040192616 A1

TITLE: Phenolic acid salts of gabapentin in solid dosage forms and methods of use

PUBLICATION-DATE: September 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kiel, Jeffrey S.	Gainesville	GA	US
Thomas, H. Greg	Villa Rica	GA	US
Mani, Narasimhan	Port Jefferson	NY	US

US-CL-CURRENT: 514/23; 514/561

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 19. Document ID: US 20040180949 A1

L5: Entry 19 of 31

File: PGPB

Sep 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040180949
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040180949 A1

TITLE: DHA-pharmaceutical agent conjugates of taxanes

PUBLICATION-DATE: September 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Shashoua, Victor E.	Brookline	MA	US
Swindell, Charles E.	Merion	PA	US
Webb, Nigel L.	Bryn Mawr	PA	US
Bradley, Matthews O.	Laytonsville	MD	US

US-CL-CURRENT: 514/449; 549/510

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 20. Document ID: US 20040106589 A1

L5: Entry 20 of 31

File: PGPB

Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106589
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040106589 A1

TITLE: Fatty acid-pharmaceutical agent conjugates

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Webb, Nigel L.	Bryn Mawr	PA	US
Bradley, Matthews O.	Laytonsville	MD	US
Swindell, Charles S.	Merion	PA	US
Shashoua, Victor E.	Brookline	MA	US

US-CL-CURRENT: 514/182; 514/549

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L3 and (514/\$ or 560/\$)

31

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 21 through 30 of 31 returned.

☐ 21. Document ID: US 20030091624 A1

L5: Entry 21 of 31

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030091624

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030091624 A1

TITLE: Simethicone solid oral dosage form

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Szymczak, Christopher E.	Marlton	NJ	US
Walter, James T.	Ambler	PA	US

US-CL-CURRENT: [424/465](#); [424/653](#), [424/94.61](#), [514/63](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 22. Document ID: US 20030008004 A1

L5: Entry 22 of 31

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008004

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008004 A1

TITLE: Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Vilkov, Zalman	Dingman's Ferry	PA	US

US-CL-CURRENT: [424/465](#); [514/561](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 23. Document ID: US 20020099013 A1

L5: Entry 23 of 31

File: PGPB

Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020099013

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020099013 A1

TITLE: Active agent delivery systems and methods for protecting and administering active agents

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Piccariello, Thomas	Blacksburg	VA	US
Olon, Lawrence P.	Bristol	TN	US
Kirk, Randal J.	Radford	VA	US

US-CL-CURRENT: 514/12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 24. Document ID: US 20020010208 A1

L5: Entry 24 of 31

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010208

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020010208 A1

TITLE: Dha-pharmaceutical agent conjugates of taxanes

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Shashoua, Victor	Brookline	MA	US
Swindell, Charles	Merion	PA	US
Webb, Nigel	Bryn Mawr	PA	US
Bradley, Matthews	Layton	PA	US

US-CL-CURRENT: 514/449

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 25. Document ID: US 20010002404 A1

L5: Entry 25 of 31

File: PGPB

May 31, 2001

PGPUB-DOCUMENT-NUMBER: 20010002404
PGPUB-FILING-TYPE: new-utility
DOCUMENT-IDENTIFIER: US 20010002404 A1

TITLE: Fatty acid-pharmaceutical agent conjugates

PUBLICATION-DATE: May 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Webb, Nigel L.	Bryn Mawr	PA	US
Bradley, Matthews O.	Laytonsville	MD	US
Swindell, Charles S.	Merion	PA	US
Shashoua, Victor E.	Brookline	MA	US

US-CL-CURRENT: 514/560; 514/558

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 26. Document ID: US 7199151 B2

L5: Entry 26 of 31

File: USPT

Apr 3, 2007

US-PAT-NO: 7199151

DOCUMENT-IDENTIFIER: US 7199151 B2

TITLE: DHA-pharmaceutical agent conjugates of taxanes

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20040180949 A1	September 16, 2004

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	---------

☐ 27. Document ID: US 6992076 B2

L5: Entry 27 of 31

File: USPT

Jan 31, 2006

US-PAT-NO: 6992076

DOCUMENT-IDENTIFIER: US 6992076 B2

TITLE: Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration

PRIOR-PUBLICATION:

DOC-ID	DATE
US 20020151529 A1	October 17, 2002

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 28. Document ID: US 6602902 B2

L5: Entry 28 of 31

File: USPT

Aug 5, 2003

US-PAT-NO: 6602902

DOCUMENT-IDENTIFIER: US 6602902 B2

**** See image for Certificate of Correction ****

TITLE: Dha-pharmaceutical agent conjugates to improve tissue selectivity

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 29. Document ID: US 6576636 B2

L5: Entry 29 of 31

File: USPT

Jun 10, 2003

US-PAT-NO: 6576636

DOCUMENT-IDENTIFIER: US 6576636 B2

TITLE: Method of treating a liver disorder with fatty acid-antiviral agent conjugates

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

☐ 30. Document ID: US 6294198 B1

L5: Entry 30 of 31

File: USPT

Sep 25, 2001

US-PAT-NO: 6294198

DOCUMENT-IDENTIFIER: US 6294198 B1

**** See image for Certificate of Correction ****

TITLE: Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

L3 and (514/\$ or 560/\$)

31

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[First Hit](#)[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 31 through 31 of 31 returned.

☐ 31. Document ID: US 5795909 A

L5: Entry 31 of 31

File: USPT

Aug 18, 1998

US-PAT-NO: 5795909

DOCUMENT-IDENTIFIER: US 5795909 A

TITLE: DHA-pharmaceutical agent conjugates of taxanes

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw D
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	--------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
L3 and (514/\$ or 560/\$)	31

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

=> s 60142-96-3 and tann?

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L2 1539 L1

64728 TANN?

L3 11 L2 AND TANN?

=> s l3 and py<2003

22870425 PY<2003

L4 2 L3 AND PY<2003

=> d 1-2 ibib abs hitstr

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1311702 CAPLUS

DOCUMENT NUMBER: 144:57525

TITLE: Coated vaginal devices for vaginal delivery of
therapeutically effective and/or health-promoting
agents

INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti,
Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S.
Ser. No. 126,863

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515 <--
US 6086909	A	20000711	US 1999-249963	19990212 <--
US 6572874	B1	20030603	US 2000-626025	20000727
NZ 508130	A	20020301	NZ 2000-508130	20001113 <--
AU 765269	B2	20030911	AU 2001-54192	20010703
US 2003049302	A1	20030313	US 2002-226667	20020821
US 6982091	B2	20060103		
US 2004005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 2004043071	A1	20040304	US 2003-600849	20030620
US 2005249774	A1	20051110	US 2005-126863	20050510
PRIORITY APPLN. INFO.:			US 1997-49325P	P 19970611
			US 1998-79897	A2 19980515
			US 1999-249963	A2 19990212
			US 2000-626025	A2 20000727
			US 2002-226667	A2 20020821
			US 2003-349029	A2 20030122
			US 2003-600849	A2 20030620
			US 2004-587454P	P 20040712


US 2005-126863 A2 20050510
 AU 1998-76976 A3 19980610
 NZ 1998-502120 A1 19980610
 US 1999-146218P P 19990728
 US 2001-315877P P 20010829
 US 2002-390748P P 20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

IT 60142-96-3, Gabapentin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents)

RN 60142-96-3 CAPLUS

CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:725436 CAPLUS

DOCUMENT NUMBER: 133:301171

TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406 <--
CA 2366702	A1	20001012	CA 2000-2366702	20000316 <--
EP 1165048	A1	20020102	EP 2000-916547	20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
 WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a

hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025,

Tween-20


0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

IT 60142-96-3, Gabapentin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 60142-96-3 CAPLUS

CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 60142-96-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexaneacetic acid, 1-(aminomethyl)- (CA INDEX NAME)
OTHER NAMES:
CN 1-(Aminomethyl)cyclohexaneacetic acid
CN CI 945
CN Gabapentin
CN Go 3450
CN GOE 2450
CN GOE 3450
CN Neurontin
MF C9 H17 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM,
DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER,
USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1530 REFERENCES IN FILE CA (1907 TO DATE)
48 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1539 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.35	7.56

FILE 'CAPLUS' ENTERED AT 16:29:53 ON 10 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

1
FILE COVERS 1907 - 10 Apr 2007 VOL 146 ISS 16
FILE LAST UPDATED: 9 Apr 2007 (20070409/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 60142-96-3 and tannic acid

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L3 1539 L2

8242 TANNIC
4349299 ACID
6641 TANNIC ACID
(TANNIC(W)ACID)

L4 5 L3 AND TANNIC ACID

=> s l4 and py<2003

22870425 PY<2003

L5 0 L4 AND PY<2003

=> s 60142-96-3 and tan?

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L7 1539 L6

447457 TAN?

L8 30 L7 AND TAN?

=> s l8 and py<2003

22870425 PY<2003

L9 6 L8 AND PY<2003

=> d 1-6 ibib abs

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1311702 CAPLUS

DOCUMENT NUMBER: 144:57525

TITLE: Coated vaginal devices for vaginal delivery of
therapeutically effective and/or health-promoting
agents

INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti,

PATENT ASSIGNEE(S): Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
 SOURCE: USA
 U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S.
 Ser. No. 126,863
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515 <--
US 6086909	A	20000711	US 1999-249963	19990212 <--
US 6572874	B1	20030603	US 2000-626025	20000727
NZ 508130	A	20020301	NZ 2000-508130	20001113 <--
AU 765269	B2	20030911	AU 2001-54192	20010703
US 2003049302	A1	20030313	US 2002-226667	20020821
US 6982091	B2	20060103		
US 2004005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 2004043071	A1	20040304	US 2003-600849	20030620
US 2005249774	A1	20051110	US 2005-126863	20050510
PRIORITY APPLN. INFO.:			US 1997-49325P	P 19970611
			US 1998-79897	A2 19980515
			US 1999-249963	A2 19990212
			US 2000-626025	A2 20000727
			US 2002-226667	A2 20020821
			US 2003-349029	A2 20030122
			US 2003-600849	A2 20030620
			US 2004-587454P	P 20040712
			US 2005-126863	A2 20050510
			AU 1998-76976	A3 19980610
			NZ 1998-502120	A1 19980610
			US 1999-146218P	P 19990728
			US 2001-315877P	P 20010829
			US 2002-390748P	P 20020621
AB	Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.			
L9	ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN			
ACCESSION NUMBER:	2001:166991 CAPLUS			
DOCUMENT NUMBER:	134:347928			
TITLE:	Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study			
AUTHOR(S):	Ifa, Demian R.; Falci, Marcio; Moraes, Maria E.; Bezerra, Fernando A. F.; Moraes, Manoel O.; De Nucci, Gilberto			
CORPORATE SOURCE:	Cartesius Analytical Unit, Department of Pharmacology, ICB-University of Sao Paulo, Sao Paulo, 05508-900, Brazil			
SOURCE:	Journal of Mass Spectrometry (2001), 36(2), 188-194			
	CODEN: JMSPFJ; ISSN: 1076-5174			
PUBLISHER:	John Wiley & Sons Ltd.			

DOCUMENT TYPE: Journal
LANGUAGE: English

AB A rapid, sensitive and specific anal. method was developed and validated to quantify gabapentin in human plasma using acetaminophen as an internal standard. The method employs a single plasma protein precipitation. The analytes are

chromatographed on a C4 reversed-phase chromatog. column and analyzed by mass spectrometry in the multiple reaction monitoring (MRM) mode. The method has a chromatog. run time of 4 min and a linear calibration curve over the range 50-10000 ng ml⁻¹ ($r > 0.999$). The between-run precision, based on the relative standard deviation for replicate quality controls, was $\leq 4.8\%$ (200 ng ml⁻¹), 6.0% (1000 ng ml⁻¹) and 4.4% (5000 ng ml⁻¹). The between-run accuracy was ± 2.6 , 4.4 and 0.5% for the above-mentioned concns., resp. This method was employed in a bioequivalence study of two gabapentin capsule formulations (Progresse from Biosintetica, Brazil, as a test formulation, and Neurotin from Parke-Davis, as a reference formulation) in 24 healthy volunteers of both sexes who received a single 300 mg dose of each formulation. The study was conducted using an open, randomized, two-period crossover design with a 7-day washout interval. The 90% confidence interval (CI) of the individual ratio geometric mean for Progresse/Neurotin was 87.9-115.6% for AUC(0-36 h) and 88.6-111.7% for C_{max}. Since both 90% CI for AUC(0-36 h) and C_{max} were included in the 80-125% interval proposed by the US Food and Drug Administration, Progresse was considered bioequivalent to Neurotin according to both the rate and extent of absorption.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:725436 CAPLUS

DOCUMENT NUMBER: 133:301171

TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.

PATENT ASSIGNEE(S): Lipocine, Inc., USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6383471	B1	20020507	US 1999-287043	19990406 <--
CA 2366702	A1	20001012	CA 2000-2366702	20000316 <--
EP 1165048	A1	20020102	EP 2000-916547	20000316 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of

ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025,

Tween-20

0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:187585 CAPLUS

DOCUMENT NUMBER: 132:288194

TITLE: Drug monitoring by electrospray tandem mass spectrometry

AUTHOR(S): Huesgen, G.; Roos, Christine; Kinkeldei, J.

CORPORATE SOURCE: Laborarztpraxis Leinfelden, Echterdingen, D-70771, Germany

SOURCE: Laboratoriumsmedizin (2000), 24(1), 14-19

CODEN: LABOD3; ISSN: 0342-3026

PUBLISHER: Blackwell Wissenschafts-Verlag GmbH

DOCUMENT TYPE: Journal; General Review

LANGUAGE: German

AB A review with 21 refs. is given. High performance liquid chromatog. is a universal tool for the quantitation of drugs or medications in blood. Light absorption and fluorescence is mostly used for detection. Some drugs do not have chromophores or have low molar absorptivities. So quantitation is difficult at low concns. Tandem mass spectrometry (LC-MS/MS) does not have these restrictions. The authors demonstrate the usefulness of LC-MS/MS in the quantitation of gabapentin, vigabatrin, amantadine, and haloperidol. Sample preparation is simple and fast. Large sample series can be analyzed cost-effectively and within a short time.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:547859 CAPLUS

DOCUMENT NUMBER: 129:285902

TITLE: Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation

AUTHOR(S): Ettinger, Alan B.; Weisbrot, Deborah M.; Saracco, Jennifer; Dhoon, Aliasgar; Kanner, Andres; Devinsky, Orrin

CORPORATE SOURCE: Department of Neurology, State University of New York at Stony Brook, Stony Brook, NY, 11794-8121, USA

SOURCE: Epilepsia (1998), 39(8), 874-877

CODEN: EPILAK; ISSN: 0013-9580

PUBLISHER: Lippincott-Raven Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This article describes significant pos. or neg. psychotropic effects of lamotrigine (LTG) observed in epilepsy patients with mental retardation (MR). Seven mentally retarded epilepsy patients, [5 with Lennox-Gastaut syndrome (LGS)] who experienced significant behavioral improvements or worsening after addition of LTG to their medication regimen were studied. LTG produced behavioral improvements in 4 patients. Patient 1, a 14-yr-old girl, had LTG added to valproate (VPA) and thioridazine, resulting in diminished

lethargy, less hyperactivity, and more appropriate speech. In a 17-yr-old boy (patient 2) LTG added to VPA, phenytoin (PHT), and gabapentin (GBP) lessened irritability and hyperactivity. In patient 3, a 41-yr-old woman, LTG added to PHT, VPA, and carbamazepine (CBZ) diminished lethargy and enhanced her social interactions. In patient 4, a 27-yr-old man, LTG monotherapy diminished irritability and hyperactivity. Adverse behavioral effects were noted in 3 patients. In patient 5, a 43-yr-old man, LTG added to PHT, phenobarbital (PB), lorazepam, sertraline, and thioridazine produced irritability, hyperactivity, and poor cooperation. In patient 6, a 29-yr-old woman, LTG added to VPA produced frequent screaming, temper tantrums, increased rocking movements, and hyperactivity. In patient 7, a 29-yr-old man, LTG added to VPA and PHT resulted in severe exacerbation of baseline behaviors, including self-injurious activity, temper tantrums, and failure to obey simple instructions. In some patients with epilepsy and MR, LTG has significant pos. or neg. effects on behavior.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:125297 CAPLUS

DOCUMENT NUMBER: 124:219452

TITLE: Behavioral side effects of gabapentin in children

AUTHOR(S): Lee, D. O.; Steingard, R. J.; Cesena, M.; Helmers, S. L.; Riviello, J. J.; Mikati, M. A.

CORPORATE SOURCE: School Medicine, Emory University, Atlanta, GA, 30322, USA

SOURCE: Epilepsia (1996), 37(1), 87-90

CODEN: EPILAK; ISSN: 0013-9580

PUBLISHER: Lippincott-Raven

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We report 7 children who received gabapentin (GBP) as adjunctive medication and subsequently developed behavioral side effects. These behavioral changes consisted of intensification of baseline behaviors as well as new behavioral problems. Behaviors that parents considered most troublesome were tantrums, aggression directed toward others, hyperactivity, and defiance. All behavioral changes were reversible and were managed by dose reduction or discontinuation of GBP. All children had baseline attention deficit hyperactivity disorder and developmental delays.

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1311702 CAPLUS
DOCUMENT NUMBER: 144:57525
TITLE: Coated vaginal devices for vaginal delivery of
therapeutically effective and/or health-promoting
agents
INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti,
Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S.
Ser. No. 126,863
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515 <--
US 6086909	A	20000711	US 1999-249963	19990212 <--
US 6572874	B1	20030603	US 2000-626025	20000727
NZ 508130	A	20020301	NZ 2000-508130	20001113 <--
AU 765269	B2	20030911	AU 2001-54192	20010703
US 2003049302	A1	20030313	US 2002-226667	20020821
US 6982091	B2	20060103		
US 2004005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 2004043071	A1	20040304	US 2003-600849	20030620
US 2005249774	A1	20051110	US 2005-126863	20050510
PRIORITY APPLN. INFO.:			US 1997-49325P	P 19970611
			US 1998-79897	A2 19980515
			US 1999-249963	A2 19990212
			US 2000-626025	A2 20000727
			US 2002-226667	A2 20020821
			US 2003-349029	A2 20030122
			US 2003-600849	A2 20030620
			US 2004-587454P	P 20040712
			US 2005-126863	A2 20050510
			AU 1998-76976	A3 19980610
			NZ 1998-502120	A1 19980610
			US 1999-146218P	P 19990728
			US 2001-315877P	P 20010829
			US 2002-390748P	P 20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:725436 CAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of
ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406 <--
CA 2366702	A1	20001012	CA 2000-2366702	20000316 <--
EP 1165048	A1	20020102	EP 2000-916547	20000316 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025,

Tween-20

0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>